Most Recent Annual Report
Upgrade your company profile to unlock all of your annual report content on AnnualReports.com
2019 Annual Report and Form 10K
Cabaletta Bio, Inc. has reached its limit for free report views.
Work for Cabaletta Bio, Inc.?
Claim Your Profile
Cabaletta Bio, Inc.
About Cabaletta Bio, Inc.
11-50 Employees
Based in Philadelphia, Pennsylvania
Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The Cabaletta Approach to selective B cell Ablation (CABA) platform, in combination with Cabaletta’s proprietary technology, utilizes Chimeric AutoAntibody Receptor (CAAR) T cells that are designed to selectively bind and eliminate only specific autoantibody-producing B cells while sparing normal antibody-producing B cells, which are essential for human health. The Company’s lead product candidate, DSG3-CAART, is being evaluated in the DesCAARTes™ Phase 1 clinical trial as a potential treatment for patients with mucosal pemphigus vulgaris, a prototypical B cell-mediated autoimmune disease. The FDA granted Fast Track Designation for DSG3-CAART in May 2020. For more information about the DesCAARTes™ Phase 1 clinical trial, please see www.clinicaltrials.gov. The Company’s lead preclinical product candidate, MuSK-CAART, is in IND-enabling studies and is designed as a potential treatment for patients with MuSK-associated myasthenia gravis.
- Ticker:
- CABA
- Exchange:
- NASDAQ (See More NASDAQ Companies)
- Industry:
- Biotechnology (See More Biotechnology Companies)
- Sector:
- Healthcare (See More Healthcare Companies)
